What is the recommended dosing and schedule of bevacizumab for newly diagnosed stage III–IV epithelial ovarian, fallopian tube, or primary peritoneal cancer and for recurrent disease?

Bevacizumab Dosing and Schedule in Ovarian Cancer

For newly diagnosed stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer, bevacizumab should be administered at 15 mg/kg IV every 3 weeks starting with cycle 2 of paclitaxel/carboplatin chemotherapy and continued for up to 22 cycles total (approximately 15 months of maintenance), or alternatively at 7.5 mg/kg IV every 3 weeks starting with cycle 1 for 5-6 cycles followed by maintenance for up to 12 additional cycles. 1

Newly Diagnosed Advanced Disease (Stage III-IV)

Two FDA-Approved Regimens:

GOG-218 Protocol (Category 2B):

• Paclitaxel 175 mg/m² IV over 3 hours + carboplatin AUC 6 IV on Day 1, every 3 weeks × 6 cycles
• Bevacizumab 15 mg/kg IV starting Day 1 of cycle 2, every 3 weeks for up to 22 cycles total (includes the 5 cycles with chemotherapy + 17 maintenance cycles)
• Total bevacizumab duration: approximately 15 months 1, 2

ICON-7 Protocol (Category 2B):

• Paclitaxel 175 mg/m² IV over 3 hours + carboplatin AUC 5-6 IV + bevacizumab 7.5 mg/kg IV on Day 1, every 3 weeks × 5-6 cycles
• Continue bevacizumab maintenance for up to 12 additional cycles
• Total bevacizumab duration: approximately 12-15 months 1

Key Evidence Points:

The 2016 NCCN guidelines upgraded bevacizumab from category 3 to category 2B for first-line therapy, reflecting evolving evidence 1. The 2019 ESMO-ESGO consensus strongly recommends bevacizumab (15 mg/kg or 7.5 mg/kg every 3 weeks for maximum 15 months) as it improves PFS in stage III-IV disease, with Level I evidence and Grade A recommendation 3.

Critical consideration: Post-hoc analyses showed OS benefit specifically in high-risk patients (stage IV disease or stage III with >1 cm residual disease) 3. However, the 2023 ESMO guidelines recommend bevacizumab for all stage III-IV patients with Grade A recommendation 4.

Extended Duration Data:

The BOOST trial (2023) definitively showed that extending bevacizumab beyond 15 months to 30 months provides NO additional benefit in PFS (HR 0.99) or OS (HR 1.04), with increased toxicity 5. Therefore, 15 months remains the standard maximum duration 5.

Recurrent Disease

Platinum-Resistant Disease:

FDA-approved dosing 2:

• 10 mg/kg IV every 2 weeks in combination with:
  • Paclitaxel (weekly), OR
  • Pegylated liposomal doxorubicin, OR
  • Topotecan (weekly)
• 15 mg/kg IV every 3 weeks with topotecan (every 3 weeks)

Real-world efficacy data: The 10 mg/kg Q2W regimen showed 26.1% ORR, with particularly favorable responses when combined with paclitaxel (53.0% ORR) versus liposomal doxorubicin (15.0%) 6. A GOG phase II trial of bevacizumab 15 mg/kg every 21 days as monotherapy showed 21% response rate and 40.3% of patients progression-free at 6 months 7.

Platinum-Sensitive Recurrent Disease:

Recommended regimen:

• Carboplatin + paclitaxel (or gemcitabine) + bevacizumab 15 mg/kg IV every 3 weeks
• Continue bevacizumab as single-agent maintenance until progression 2, 8

Neoadjuvant Setting

Bevacizumab can be safely administered in the neoadjuvant setting 3, 4:

• Standard dosing: 15 mg/kg every 3 weeks with carboplatin/paclitaxel
• Critical timing: Stop bevacizumab 4-6 weeks before interval debulking surgery
• Resume at least 4-6 weeks after surgery once adequate wound healing confirmed 3
• Level II evidence, Grade B recommendation 3

Administration Details

Infusion schedule 2:

• First infusion: 90 minutes
• Second infusion: 60 minutes (if first tolerated)
• Subsequent infusions: 30 minutes (if second tolerated)

Surgical considerations 2:

• Withhold for at least 28 days prior to elective surgery
• Do not resume until at least 28 days after major surgery AND adequate wound healing confirmed

Common Pitfalls to Avoid

1. Do not extend beyond 15 months in first-line setting—no benefit, increased toxicity 5
2. Do not use with anthracyclines—increased CHF risk 2
3. Screen for GI perforation risk factors: inflammatory bowel disease history, large bowel resections at debulking surgery 3
4. Monitor closely: hypertension (most common grade 3+ toxicity at 20-25%), proteinuria (discontinue if ≥2g/24h or nephrotic syndrome) 1, 3
5. Adequate surgical timing: Strict adherence to 4-6 week intervals prevents wound complications 3, 2